ImmunoCheckDB: A Comprehensive Platform for Evaluating Cancer Immunotherapy Biomarkers Through Meta-Analyses and Multiomic Profiling

Abstract

Immune checkpoint inhibitors (ICIs) have transformed cancer immunotherapy, but their clinical efficacy varies significantly due to tumor heterogeneity and patient-specific factors. Existing databases lack comprehensive integration of ICI efficacy data and fail to explore biomarkers across pan-cancer contexts, limiting their utility in precision oncology. To address this gap, we developed ImmunoCheckDB, a systematic platform that curates 173 studies on cancer ICI treatment, integrating survival outcomes for traditional and network meta-analyses with multiomic data sets from public repositories, including over 93,000+ individuals across 18 cancer types and 30 ICI regimens to provide a robust resource for pan-cancer biomarker discovery. Equipped with online tools for meta-analysis, network meta-analysis, and multiomic profiling, ImmunoCheckDB enables researchers to investigate correlations between ICI efficacy and molecular biomarkers, featuring key functionalities such as real-time visualization of forest plots, funnel plots, and network diagrams, as well as association analyses linking multiomic data to clinical outcomes. Uniquely combining meta-analytical with multiomic exploration, our platform offers insights into optimal patient populations for ICI therapy, thereby bridging the gap between clinical data and molecular research to empower researchers in advancing precision immunotherapy, with access available at https://smuonco.shinyapps.io/ImmunoCheckDB/ to democratize data-driven insights for personalized cancer treatment.